The Baxter/WHO case
| < Prev |
|---|

In February 2009, Baxter’s Austrian subsidiary in Orth an der Donau manufactured and distributed 72 kilos of vaccine material, contaminated with a H5N1 virus, to 16 laboratories in four countries.
In February 2009, Baxter’s Austrian subsidiary in Orth an der Donau manufactured and distributed 72 kilos of vaccine material, contaminated with a H1N1 virus, to 16 laboratories in four countries, including Austria, so nearly triggering a pandemic, according to The Times of India.
The contaminated vaccine material consisted of a mixture of a seasonal H3N2 human influenza virus and the deadly H5N1 virus. By adding a virus of the type H5N1 to an ordinary flu virus of the type H3N2, Baxter produced a highly dangerous bioweapon. WHO supplied Baxter with the live bird flu virus. A staff member of a subcontracted laboratory in the Czech Republic discovered this lethal contamination, when all animals they tested died from this vaccine.
Since Baxter is obliged to use BSL 3 (Biosafety Level 3) precautions in its laboratories when handling the H1N1 virus (classified as a biological agent, BSL3 or 4 under EU regulations), such safeguards are in place as would make accidental contamination of ordinary influenza material with the dangerous H1N1 virus impossible.
In other words, this deadly contamination and distribution was almost certainly due to criminal intent. Thirty-six people had to be preventatively hospitalized in Austria and the Czech Republic because of their exposure to this vaccine-based contamination, underlining the danger.
On April 8th, I filed my first set of criminal charges with the Vienna City Prosecutor and the police in Austria are now investigating.
I have subsequently filed more charges over the Austrian government's cover up in July, a bioterrorism incident in a Swiss train in April and set of charges at the FBI at the US embassy in Vienna in June over the "swine flu"outbreak.
| Comments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|


















